CADTH Provisional Funding Algorithms


( Last Updated : January 31, 2023)

1. About Provisional Funding Algorithms 

The provisional algorithm process is used to provide advice to drug programs when they have indicated that there is need to establish an appropriate place in therapy for new oncology drugs relative to alternative treatments that are currently reimbursed by the drug programs. The process ascertains the impact of new therapies on the sequencing of treatments for the purposes of reimbursement (e.g., should reimbursing a new drug result in a shift or a displacement of other available treatments). While broad in scope, funding algorithms are focused on reimbursement decision-making; they are not treatment algorithms or guidelines and do not fully detail the clinical management of cancer patients.

CADTH will initiate the development of a provisional algorithm in the following instances:

  • following issuance of a recommendation in favour of the reimbursement of a drug with the potential to impact the existing funding algorithm for the indication of interest; or
  • when new evidence that may disrupt the sequencing of drugs is identified; and
  • when the participating drug programs indicate that a provisional algorithm is required for implementation purposes.

Please review the Procedures for CADTH Reimbursement Reviews for complete details.

2. Contribute

CADTH issues a call for stakeholder input at the time the provisional algorithm project is initiated and seeks stakeholder feedback on the draft provisional algorithm. The following stakeholders are eligible to contribute: patient groups, clinician groups, the participating drug programs, and drug manufacturers whose products may be directly impacted by the provisional algorithm.

Open calls for input and feedback are highlighted in the CADTH Weekly Update and instructions for contributing are provided below.

2.1 Initial Input on a Provisional Funding Algorithm Project

To provide initial input at the outset of the provisional algorithm project:

  • Locate the webpage for provisional algorithm project of interest from the CADTH Weekly Update or the list of current opportunities for input and feedback.
  • Review the proposed project scope for the provisional algorithm.
  • Download the stakeholder input template.
  • Complete the template by the deadline specified on the project webpage.
  • Send the completed template by clicking Submit Feedback on the project webpage.

2.2 Stakeholder Feedback on a Draft Provisional Funding Algorithm

To provide stakeholder feedback on a draft provisional algorithm report:

  • Locate the webpage for provisional algorithm project of interest from the CADTH Weekly Update or the list of current opportunities for input and feedback.
  • Review the draft provisional funding algorithm report.
  • Download the stakeholder feedback template.
  • Complete the template by the deadline specified on the project webpage.
  • Send the completed template by Submit Feedback on the project webpage.

3. CADTH Provisional Funding Algorithm Projects

Updates on CADTH provisional funding algorithms are posted to this page. Reports are searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them, and appropriate credit is given to CADTH.

Tumour Type

Therapeutic Area

Project Number

Project Status

Date Final Report Posted

Breast

HER2-positive metastatic breast cancer

PH0006-000

Complete

April 12, 2022

Breast

HER2-positive metastatic breast cancer

PH0016-000

Complete

January 13, 2023

Breast

HR+ HER2- Breast Cancer

PH0018-000

Active

-

Gastrointestinal

Unresectable Hepatocellular Carcinoma

PH0003-000

Complete

April 21, 2021

Gastrointestinal

Human Epidermal Growth Factor Receptor 2(HER2) Negative Gastric, Gastroesophageal Junction (GEJ), or Esophageal Cancer

PH0010-000

Complete

June 21, 2022

Gastrointestinal

Colon Cancer

PH0005-000

Complete

November 21, 2021

Genitourinary

Metastatic Urothelial Carcinoma

PH0008-000

Complete

March 28, 2022

Genitourinary

Metastatic Urothelial Carcinoma

PH0017-000

Complete

January 11, 2023

Genitourinary

Renal Cell Carcinoma

PH0013-000

Complete

September 6, 2022

Genitourinary

Renal Cell Carcinoma

PH0019-000

Complete

January 11, 2023

Leukemia

Adult B-cell precursor Acute Lymphoblastic Leukemia, Philadelphia chromosome negative

PH0002-000

Complete

February 24, 2021

Leukemia

Chronic Lymphocytic Leukemia

PH0004-000

Complete

May 18, 2021

Lung

Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer

PH0009-000

Complete

May 24, 2022

Lung

NSCLC without actionable oncogenic alterations

PH0012-000

Complete

August 5, 2022

Lung

NSCLC without actionable oncogenic alterations

PH0015-000

Complete

December 1, 2022

Lung

RET-fusion positive NSCLC

PH0020-000

Withdrawn

-

Lymphoma

Adult Classical Hodgkin Lymphoma

PH0007-000

Complete

May 2, 2022

Myeloma

Multiple Myeloma

PH0011-000

Complete

May 25, 2022

Myeloma

Multiple Myeloma

PH0014-000

Complete

November 14, 2022

Other

Differentiated Thyroid Carcinoma

PH0021-000

Complete

February 06, 2023

Skin & Melanoma

Melanoma

PH0022-000

Complete

February 06, 2023